Please try another search
Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of oncology products in the United States. The company offers patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development. It also provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to FDA-approved and investigational drug treatments. In addition, the company’s data-generating assays provide actionable information for physicians, patients, and biopharmaceutical companies in the area of oncology. The company was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. Theralink Technologies, Inc.is headquartered in Golden, Colorado.
Name | Age | Since | Title |
---|---|---|---|
Matthew M. Schwartz | - | 2022 | Independent Director |
Yvonne C. Fors | 51 | 2020 | Director |
Virginia Espina | - | - | Scientist |
Lance Liotta | - | - | Chairman of Medical Advisory Board |
Jeffery M. Busch | 64 | 2020 | Chairman of the Board |
Emanuel F. Petricoin | - | - | Chairman of Scientific Advisory Board |
Danica C. Holley | 51 | 2022 | Independent Director |
Michael I. Ruxin | 78 | 2020 | Chief Medical Officer & Director |
Andrew Albert Kucharchuk | 43 | 2015 | CFO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review